It is the first high-throughput, robust and economical tool to screen parasite-specific palmitoylation. also, it is first ex-vivo study of palmitoylation in bacteria, which,being a palmitoylation machinery-null system,gives exact interpretation of palmitoylation activity of parasite-specific palmitoyl-acyl-transferases in the presence of different inhibitors.high reproducibility and short generation time, compared to the existing assays makes thissystem unique and reliable. using this, chemical compound libraries can be robustly screened in a cost-effective manner so that market can come up with the newer drugs to target diseases like cancer, schizophrenia, malaria, diabetes and leishmaniasis, where protein palmitoylation is highly dis-regulated.